SYNEK, Svatopluk and Bozo VOJNIKOVIC. Intravitreal Bevacizumab With or Without Triamcinolone for Refractory Diabetic Macular... Collegium Antropologicum. Zagreb, 2010, vol. 34, Suppl. 2, p. 99-103. ISSN 0350-6134.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Intravitreal Bevacizumab With or Without Triamcinolone for Refractory Diabetic Macular...
Authors SYNEK, Svatopluk (203 Czech Republic, guarantor, belonging to the institution) and Bozo VOJNIKOVIC (191 Croatia).
Edition Collegium Antropologicum, Zagreb, 2010, 0350-6134.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30000 3. Medical and Health Sciences
Country of publisher Croatia
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 0.491
RIV identification code RIV/00216224:14110/10:00061165
Organization unit Faculty of Medicine
UT WoS 000283961100021
Keywords in English bevacizumab; diabetic macular oedema
Tags International impact
Changed by Changed by: Mgr. Michal Petr, učo 65024. Changed: 4/10/2012 14:24.
Abstract
We evaluate the effect of intravitreal injections of Bevacizumab (IVB) alone or combined with triamcinolone (IVT) in the first injection for treatment of refractor), diabetic macular oedema (DME). Sixty eyes of sixty patients with refractory DME were included. Half of the receive injections of IVB (1.25 mg/0.05 mL) or combined IVB and IVT (1.25 mg/0.05 mL and 2 mg/0.05 mL respectively). The primary outcome measure was change in central macular thickness (CMT). Secondary outcome measures were change in best-corrected logMAR visual acuity (BCVA) and incidence of potential adverse events. Central macular thickness was reduced significantly in both the IVB and IVB/IVT groups. At week 24, CMT change compared to the baseline was -95.7 mu m (95% CI, -172.2 to -19.26) in the IVB group and -92.1 mu m (95% CI, -154.4 to -29.7) in the IVB/IVT group. There was not a significant difference between the IVB and the IVB/IVT groups (p=0.022). Improvement of BCVA was initiated at weeks 6 and 12 in the IVB/IVT and IVB groups respectively. In terms of BCVA change compared to the baseline at 24 weeks, the differences between the IVB and the IVB/IVT groups (p=0.006) were significant. Anterior Chamber reaction was noticed in six (20%) and six (20%) eyes respectively in the IVB and IVB/IVT groups the day after injection, and it resolved with no sequel. Elevation of IOP occurred in two eyes (6%) in the IVB/IVT group. Intravitreal injections of Bevacizumab had a beneficial effect on refractory DME in terms of CMT reduction and BCVA improvement. Addition of triamcinolone in the injection seemed to induce earlier visual improvement; however, it did not show any significant additive effect later during follow-up.
PrintDisplayed: 9/10/2024 18:24